Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients

Uro-Oncology

Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores

Prostate

Wenzel M, Würnschimmel C, Ruvolo CC, Nocera L, Tian Z, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI

doi: 10.1002/pros.24184

Uro-Oncology

Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer

J Urol.

Ranasinghe W, Reichard CA, Nyame YA, Sundi D, Tosoian JJ, Wilkins L, Alam R, Achim MF, Wang X, Stephenson AJ, Klein EA, Ross AE, Allaf ME, Davis JW, Chapin BF

doi: 10.1097/JU.0000000000001074.

Uro-Oncology

Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients

Prostate

Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, Shariat SF, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI

doi: 10.1002/pros.24253

Uro-Oncology

Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities

Prostate.

Dee EC, Nezolosky MD, Chipidza FE, Arega MA, Butler SS, Sha ST, Mahal BA, Nguyen PL, Yang DD, Muralidhar V

doi: 10.1002/pros.24041.

Uro-Oncology

Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer

Prostate Cancer Prostatic Dis.

Nguyen PL, Martin NE, Choeurng V, Palmer-Aronsten B, Kolisnik T, Beard CJ, Orio PF, Nezolosky MD, Chen YW, Shin H, Davicioni E, Feng FY

doi: 10.1038/pcan.2016.58.

Uro-Oncology

Personalized Biopsy Schedules Based on Risk of Gleason Upgrading for Low-Risk Prostate Cancer Active Surveillance Patients

BJU Int.

Tomer A, Nieboer D, Roobol MJ, Bjartell A, Steyerberg EW, Rizopoulos D, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium

doi: 10.1111/bju.15136.

Uro-Oncology

Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer

Prostate Cancer Prostatic Dis.

Preisser F, Gandaglia G, Arad F, Karakiewicz PI, Bandini M, Pompe RS, Montorsi F, Graefen M, Huland H, Briganti A, Tilki D

doi: 10.1038/s41391-020-00266-4.

Uro-Oncology

Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT)

Eur Urol.

Wilt TJ, Vo TN, Langsetmo L, Dahm P, Wheeler T, Aronson WJ, Cooperberg MR, Taylor BC, Brawer MK

doi: 10.1016/j.eururo.2020.02.009.

Uro-Oncology

Multicenter optimization and validation of a 2-gene mRNA urine test for detection of clinically significant prostate cancer prior to initial prostate biopsy

J Urol.

Haese A, Trooskens G, Steyaert S, Hessels D, Brawer M, Vlaeminck-Guillem V, Ruffion A, Tilki D, Schalken J, Groskopf J, Van Criekinge W

doi: 10.1097/JU.0000000000000293.

Related content

Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores

Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer

Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients

Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities

Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer

Personalized Biopsy Schedules Based on Risk of Gleason Upgrading for Low-Risk Prostate Cancer Active Surveillance Patients

Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer

Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT)

Multicenter optimization and validation of a 2-gene mRNA urine test for detection of clinically significant prostate cancer prior to initial prostate biopsy